Heparin-binding EGF-like growth factor (HB-EGF) is an EGF family member that interacts with epidermal growth factor receptor (EGFR) and ERBB4. Since HB-EGF was first identified as a novel growth factor secreted from a human macrophage cell line, numerous pathological and physiological functions related to cell proliferation, migration, and inflammation have been reported. Notably, the expression of HB-EGF is sensitively upregulated by oxidative stress in the endothelial cells and functions for auto- and paracrine-EGFR signaling. Overnutrition and obesity cause elevation of HB-EGF expression and EGFR signaling in the hepatic and vascular systems. Modulations of HB-EGF signaling showed a series of protections against phenotypes related to metabolic syndrome and advanced metabolic diseases, suggesting HB-EGF as a potential target against metabolic diseases.
|Number of pages||11|
|Journal||Metabolic Syndrome and Related Disorders|
|State||Published - May 1 2020|
Bibliographical noteFunding Information:
This study was supported by the National Institutes of Health K99/R00 HL105577 (S.L.) and the American Heart Association 17GRNT33700302 (S.L.).
© Copyright 2020, Mary Ann Liebert, Inc., publishers 2020.
- endothelial cells
- metabolic syndrome
ASJC Scopus subject areas
- Internal Medicine
- Endocrinology, Diabetes and Metabolism